Role of sodium channel inhibition in neuroprotection: Effect of vinpocetine

Brain Research Bulletin

Volumn 53, Issue 3, 2000, Pages 245-254

  Bönöczk, Péter ^a   Gulyás, Balázs ^b   Adam Vizi, Vera ^c   Nemes, András ^a   Kárpáti, Egon ^a   Kiss, Béla ^a   Kapás, Margit ^a   Szántay, Csaba ^d   Koncz, István ^e   Zelles, Tibor ^e   Vas, Adam ^a  

^a GEDEON RICHTER LTD   (Hungary)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS   (Hungary)

^e INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Cerebrovascular disorders; Neuroprotection; PET studies; Vinpocetine

Indexed keywords

14,15 DIHYDROEBURNAMENINE 14 METHANOL; ADENOSINE; CALCIUM CHANNEL; DIDYDROEBURNAMENINE 14 METHANOL; SODIUM CHANNEL; UNCLASSIFIED DRUG; VINBURNINE; VINBURNINE DERIVATIVE; VINCAMINE; VINPOCETINE; VINTOPEROL;

BRAIN BLOOD FLOW; CEREBROVASCULAR DISEASE; CHANNEL GATING; CLINICAL TRIAL; DOPPLER ECHOGRAPHY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SYNTHESIS; DRUG UPTAKE; GLUCOSE TRANSPORT; HUMAN; INFRARED SPECTROSCOPY; NEUROPROTECTION; NONHUMAN; ORGANIC PSYCHOSYNDROME; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STROKE; STRUCTURE ACTIVITY RELATION;

ANIMALS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CEREBROVASCULAR DISORDERS; HUMANS; NEUROPROTECTIVE AGENTS; VINCA ALKALOIDS;

EID: 0033663398     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(00)00354-3     Document Type: Review

References (111)

1. External Ca(2+)-independent release of neurotransmitters
2. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta
3. Comparative neuroprotective effects of pentobarbital, vinpocetine, flunarizine and ifenprodil on ischemic neuronal damage in the gerbil hippocampus
4. A mouse model of focal cerebral ischemia for screening neuroprotective drug effects
5. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction
6. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms
7. Pharmacokinetic study of Cavinton in humans
8. Calcium accumulation by glutamate receptor activation is involved in hippocampal cell damage after ischemia
9. Causes of calcium accumulation in rat cortical brain slices during hypoxia and ischemia: Role of ion channels and membrane damage
10. Effects of vincamine and vinpocetine on infarct size in focal cerebral ischemia
11. Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome
12. Preparation of vincamine derivatives as vasodilators. AT 386 202 (1988)
13. Process for preparation of apovincaminic acid ethyl ester. ES 549 105
14. Oxygen free radical involvement in ischemia and reperfusion injury to brain
15. The importance of voltage-dependent sodium channels in cerebral ischaemia
16. Neurotoxins that act on voltage-sensitive sodium channels in excitable membranes
17. Exacerbated responses to oxidative stress by an Na(+) load in isolated nerve terminals: The role of ATP depletion and rise of [Ca(2+)](i)
18. Comparative effects of vinpocetine and 8-Br-cyclic GMP on the contraction and 45Ca-fluxes in the rabbit aorta
19. NGF mediates the neuroprotective effect of the beta2-adrenoceptor agonist clenbuterol in vitro and in vivo: Evidence from an NGF-antisense study
20. Syntheses and cardiovascular activity of stereoisomers and derivatives of eburnane alkaloids
21. Vinpocetine enhances retrieval of a step-through passive avoidance response in rats
22. Detection of intracellular free Na+ concentration of synaptosomes by a fluorescent indicator, Na(+)-binding benzofuran isophthalate: The effect of veratridine, ouabain, and alpha-latrotoxin
23. Vincamine and vincanol are potent blockers of voltage-gated Na+ channels
24. Vinpocetin protects against excitotoxic cell death in primary cultures of rat cerebral cortex
25. Symposium of pharmacology of vinca alkaloids
26. Long-term study concerning tolerance and efficacy of vinpocetine in elderly patients suffering from a mild to moderate organic psychosyndrome
27. The effect of some drugs with purported antianoxic effect on veratrine-induced purine release from isolated rat hypothalamic synaptosomes
28. A voltage-dependent persistent sodium current in mammalian hippocampal neurons
29. Efficacy and tolerance of vinpocetine in dementia
30. Vinpocetine pharmacokinetics in elderly subjects
31. Effect of vinpocetine in scopolamine-induced learning and memory impairments
32. Comparison of the effects of vinpocetine, vincamine, and nicergoline on the normal and hypoxia-damaged learning process in spontaneously hypertensive rats
33. Effect of vinpocetine in memory disturbances induced by different damaging agents
34. 11C]vinpocetine: A preliminary PET study in a cynomolgus monkey
35. 11C]vinpocetine in human subjects
36. Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle
37. Carbon-11-FLB 457: A radioligand for extrastriatal D2 dopamine receptors
38. Reactive oxygen species and the central nervous system
39. Protective effect of KB-2796, a new calcium antagonist, in cerebral hypoxia and ischemia
40. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterases
41. Neurotrophin-mediated neuroprotection by solid fetal telencephalic graft in middle cerebral artery occlusion: A preventive approach
42. Measurement of striatal H2O2 by microdialysis following global forebrain ischemia and reperfusion in the rat: Correlation with the cytotoxic potential of H2O2 in vitro
43. Comparison of the relaxant actions of M and B 22948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methyl-amino)xanthine
44. Effects of several cerebroprotective drugs on NMDA channel function: Evaluation using Xenopus oocytes and 3HMK-801 binding
45. The use of Xenopus oocytes to evaluate drugs affecting brain Ca2+ channels: Effects of bifemelane and several nootropic agents
46. Protective effects of vinpocetine and structurally related drugs on the lethal consequences of hypoxia in mice
47. Vinpocetine preferentially antagonizes quisqualate/AMPA receptor responses: Evidence from release and ligand binding studies
48. Pharmacological modification of post-ischemic brain cell injury
49. Octahydroindolo [2,3a]-aquinolizine diester derivatives. Fr. Pat. 2 648 817
50. Vinpocetine increases the neuroprotective effect of adenosine in vitro
51. Protection against veratridine toxicity in rat cortical cultures: Relationship to sodium channel blockade
52. Vinpocetine is a highly potent neuroprotectant against veratridine-induced cell death in primary cultures of rat cerebral cortex
53. Effects of vinpocetine in four pharmacological models of cerebral ischaemia
54. Effects of isozyme-selective phosphodiesterase inhibitors on rat aorta and human platelets: Smooth muscle tone, platelet aggregation and cAMP levels
55. Intracellular calcium levels and calcium fluxes in the CA1 region of the rat hippocampal slice during in vitro ischemia: Relationship to electrophysiological cell damage
56. Bioavailability of vinpocetine and interference of the time of application with food intake
57. Alkaloid esters. Ger. Offen. 2 253 750
58. The synthesis of ethyl apovincaminate
59. Sodium channel blockers reduce oxygen-glucose deprivation-induced cortical neuronal injury when combined with glutamate receptor antagonists
60. Neuroprotective effects of tetrodotoxin as a Na+ channel modulator and glutamate release inhibitor in cultured rat cerebellar neurons and in gerbil global brain ischemia
61. A double-blind clinical trial of vinpocetine in the treatment of cerebral insufficiency of vascular and degenerative origin
62. Inhibitory effect of hypoxic condition on acetylcholine release is partly due to the effect of adenosine released from the tissue
63. Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans
64. Effect of age on the pharmacokinetics of vinpocetine (Cavinton) and apovincaminic acid
65. Antioxidants protect against glutamate-induced cytotoxicity in a neuronal cell line
66. Vinpocetine is as potent as phenytoin to block voltage-gated Na+ channels in rat cortical neurons
67. Activation of sigmal receptor subtype leads to neuroprotection in the rat primary neuronal cultures
68. Ion channels as targets for neuroprotective agents
69. Alternative routes to vincamine
70. Release of glutamate, aspartate, and gamma-aminobutyric acid from isolated nerve terminals
71. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia
72. Neuroprotective strategies: Voltage-gated Na+-channel down-modulation versus presynaptic glutamate release inhibition
73. Protective effects of drugs against hypoxic damage of neuroblastoma cells tested in vitro
74. Neuroblastoma cells for testing neuroprotective drug effects
75. A double-blind placebo controlled evaluation of the efficacy and safety of vinpocetine in the treatment of patients with chronic vascular or degenerative senile cerebral dysfunction
76. Pharmacokinetics of vinpocetine and its metabolite, apovincaminic acid, in plasma and cerebrospinal fluid after intravenous infusion
77. Increased LCGU and decreased LCBF in rat hippocampus 7 days after ischemia
78. Effects of vinpocetine on local cerebral blood flow and glucose utilization seven days after forebrain ischemia in the rat
79. Protective effect of vinpocetine against brain damage caused by ischemia
80. Biochemical effects of ethyl apovincaminate
81. Effects of glucose deprivation, chemical hypoxia, and simulated ischemia on Na+ homeostasis in rat spinal cord astrocytes
82. The neurotoxicity of excitatory amino acids is produced by passive chloride influx
83. Synaptosomal response to oxidative stress: Effect of vinpocetine
84. Vinpocetine prevents ischemic cell damage in rat hippocampus
85. Blockade of voltage-sensitive sodium channels by NS-7, a novel neuroprotective compound, in the rat brain
86. Vinpocetine selectively inhibits neurotransmitter release triggered by sodium channel activation
87. Study on the possible involvement of protein kinases in the modulation of brain presynaptic sodium channels; comparison with calcium channels
88. Indole derivatives as neuroprotectants
89. Mechanisms of calcium and sodium fluxes in anoxic myelinated central nervous system axons
90. Na(+)-Ca2+ exchanger mediates Ca2+ influx during anoxia in mammalian central nervous system white matter
91. Ionic mechanisms of anoxic injury in mammalian CNS white matter: Role of Na+ channels and Na(+)-Ca2+ exchanger
92. A new synthetic route to (+)-vincaminic and (+)-apovincaminic esters
93. New route to the stereoselective synthesis of (+)-vincamine, (-)-vincamone, and (+)-apovincaminic acid esters
94. Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: A PET study
95. The eburnamine-vincamine group
96. Preparation of apovincaminic acid esters. Ger.Pat.3 222 096
97. Vasodilator and angioprotective activity of 1-ethyl-1-hydroxyalkyl-octahydroindolo [2,3]-a quinolizine derivatives
98. PCT Int Appl WO 9 210 495
99. Cerebroprotective action of naftidrofuryl oxalate I: Prolongation of survival time and protection of cerebral energy metabolism in bilateral carotid artery-ligated mice
100. Na+ currents that fail to inactivate
101. Oxygen/glucose deprivation in hippocampal slices: Altered intraneuronal elemental composition predicts structural and functional damage
102. The neuroprotective drug vinpocetine prevents veratridine-induced [Na+]i and [Ca2+]i rise in synaptosomes
103. Dexamethasone effects on cerebral protein synthesis prior to and following hypoxia-ischemia in immature rat
104. Pharmacological modulation of voltage-gated Na+ channels: A rational and effective strategy against ischemic brain damage
105. Ammonium succinate: An effective corrector of circulatory cerebral hypoxia
106. Pharmacokinetics and metabolism of vincamine and related compounds
107. Damage from oxygen and glucose deprivation in hippocampal slices is prevented by tetrodotoxin, lidocaine and phenytoin without blockade of action potentials
108. Anti-anoxic effects of VA-045
109. Cerebral vasodilators potentiate the anti-anoxic activity of indeloxazine hydrochloride, a new cerebral activator
110. Cytosolic Ca2+ changes during in vitro ischemia in rat hippocampal slices: Major roles for glutamate and Na+-dependent Ca2+ release from mitochondria